Medivation ( MDVN) and Astellas Drug/indication: Enzalutamide (MDV3100) for prostate cancer Approval decision date: Nov. 22 GlaxoSmithKline ( GSK) and Ligand Pharmaceuticals ( LGND) Drug/indication: Promacta for thrombocytopenia in hepatitis C patients Approval decision date: Nov. 30 Alexza Pharmaceuticals ( ALXA) Drug/indication: Adasuve for agitation due to schizophrenia Approval decision date: Dec. 21 This is Alexza's third attempt at Adasuve approval. Biogen Idec ( BIIB) Drug/indication: BG-12 for multiple sclerosis Approval decision date: Dec. 28 BG-12 would be Biogen's first pill for multiple sclerosis. NPS Pharmaceuticals ( NPSP) Drug/indication: Gattex for short bowel syndrome Approval decision date: Dec. 30 Santarus Drug/indication: Uceris for ulcerative colitis Approval decision date: Jan. 16, 2013 NuPathe ( PATH) Drug/indication: Zelrix for migraine Approval decision date: Jan. 17, 2013 This is NuPathe's second attempt at Zelrix approval. Raptor Pharmaceutical ( RPTP) Drug/indication: RP103 for cystinosis Approval decision date: Jan. 30, 2013 Hemispherx Biopharma ( HEB) Drug/indication: Ampligen for chronic fatigue syndrome Approval decision date: Feb. 1, 2013 Celgene ( CELG) Drug/indication: Pomalidomide for multiple myeloma Approval decision date: Feb. 10, 2013 Dynavax ( DVAX) Drug/indication: Heplisav for hepatitis B prevention Approval decision date: Feb. 24, 2013 Zogenix ( ZGNX) Drug/indication: Zohydro for chronic pain Approval decision date: March 1, 2013 Sanofi ( SNY) Drug/indication: Lemtrada for multiple sclerosis Approval decision date: April 12, 2013 Johnson & Johnson ( JNJ) Drug/indication: Zytiga for prostate cancer Approval decision date: April 15, 2013 J&J is seeking an expanded label for Zytiga to treat "pre-chemo" prostate cancer patients. Sources: Company reports, TheStreet research, BioMedTracker --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.